Prof. Dr. Steffen Augsberg
- Born in 1976
- Since 2013 Professor of Public Law at the University of Giessen
- 2011 – 2013 Professor of Public Law and Health Care Law at Saarland University
- 2011 Habilitation at the University of Cologne
- 2004 – 2011 Assistant Professor at the Institute of Constitutional Law at the University of Cologne
- 2004 Second State Examination
- 2002 – 2004 Legal Clerkship at the District Court of Lübeck
- 2002 PhD as Dr. iur. at the University of Heidelberg
- 2000 – 2001 Research Assistant at the Institute for German and European Administrative Law at the University of Heidelberg
- 2000 First State Examination
- 1995 – 2000 Studies of law at the Universities of Trier and Munich
Jaap Jan Boelens, MD, PhD
I am Jaap Jan Boelens, a pediatrician – Oncologist / Immunologist working as consultant in Hematopoietic Cell Transplantation (HCT) at the UMC Utrecht since 2006 (and from May 2018 at the Prinses Maxima Center for Pediatric Oncology, Utrecht). I am having a special interest in rare-diseases (as indication for HCT) in particular “lysosomal storage diseases” and finding strategies to get better disease control (in malignant diseases). My research lab focuses on the development of cord blood-derived dendritic cell vaccines (anti-AML, anti-Neuroblastoma; https://youtu.be/iPoSKA2jTOo and https://youtu.be/ly1zIyQbWz0). In addition, there is a special interest in designing predictable low toxic conditioning regimens using pharmacokinetic/pharmacodynamic-models (e.g. ATG; anti-thymocyte globuline, Fludarabine) aiming for better predictable immune-reconstitution after HCT (necessary for optimal effect vaccines): www.tumor-immunology-utrecht.nl 4 PostDocs, 7 PhD students and 2 technicians are currently working in my group. I am regional VP-elect (2016-2018; VP 2018-2020) of the ISCT (international Society of Cellular Therapy), co-chair working committee benign disorders CIBMTR and member of the board of directors of the cord blood association.
Prof. Dr. Dirk Busch
- Current position: Director of the Institute for Medical Microbiology, Immunology and Hygiene, TUM School of Medicine, Technical University of Munich
- Academic training:
- 1992 – 1993 Study of Human Medicine, University of Freiburg
- 1987 – 1992 Study of Human Medicine, University of Mainz
- Academic degrees
- 2003 Habilitation; Ex vivo analysis of antigen-specific T cell responses
- 1993 Dr. med.; Immunoreactive Galanin in pancreas and intestine
- Postgraduate positions
- 2009 to date Director, Institute for Medical Microbiology and Immunology, Technical University of Munich
- 2004 – 2008 C3-Professor for Medical Microbiology and Immunology, Technical University of Munich
- 1999 – 2004 Senior Researcher, Technical University of Munich
- 1996 – 1999 Postdoctoral Researcher at the Section of Infectious Diseases and Immunobiology, Yale University, New Haven/USA
- 1994 – 1996 Postdoctoral Researcher at the Laboratory of Pediatric Rheumatology, University of Würzburg
- 1990 – 1993 Pre Doctoral Research Fellow (M.D.), Endocrinology, University of Mainz
Prof. Dr. Penelope Engel-Hills
Penelope practiced for many years as a Radiation Therapist (RTT) in the Radiation Oncology Department at Groote Schuur Hospital, Cape Town, South Africa. She also has several years work experience in Radiation Therapy in the Netherlands. Over an extended period Penelope has been an expert consultant to the International Atomic Energy Agency (IAEA) that included missions to a number of Radiation Oncology Departments on the African Continent and to the Fukushima Medical University in Japan. Towards the goal of improving radiotherapy services in Africa, Penelope is currently working with the Mauritius Institute of Health on a diploma programme to train RTTs for an expanding oncology service. Penelope’s current substantive appointment is Associate Professor: Interdisciplinary Health Sciences and for 2017 and 2018 she also occupies the position of Acting Dean in the Faculty of Health and Wellness Sciences at the Cape Peninsula University of Technology (CPUT) in Cape Town, South Africa. Her qualifications include an MSC Medical Physics, from the University of Cape Town (UCT), a Doctor of Technology: Radiography, from CPUT and a Postgraduate Diploma from UCT in International Research Ethics. Penelope has throughout her career continued in the intersecting roles of health care practitioner, educator and researcher. She strives to make a contribution in these aspects of her professional life and to enhance ethics in research and clinical practice. Penelope is an active researcher and currently has a National Research Foundation grant for 2018 – 2020 to conduct community based research on a project titled; Internationalisation for knowledge partnership and social transformation. The focus of this research is Gender-based Violence and the project is conducted in collaboration with a Swedish colleague and researcher. All her research endeavours include the supervision of postgraduate students in interdisciplinary research projects. At CPUT Penelope serves as a member of the faculty Human Research Ethics Committee, the institutional Animal Research Ethics Committee and the Senate Ethics Committee. Penelope also has a ministerial appointment to the National Health Research Ethics Council in South Africa for the period 2016 to 2019.
Prof. Ritva Halila, MD, PhD
- Born: 1958 Kemijärvi, Finland
- MD 1982, University of Oulu
- Ph.D. 1985, University of Oulu
- Specialist in Paediatrics 1997, University of Helsinki
- Docent, Medical Ethics, University of Helsinki 2007
- General Secretary, National Advisory Board on Health Care Ethics 1999-2008
- Lecturer, University of Helsinki 2009
- Head of Department (Hjelt Institute, University of Helsinki) 2010-2013
- General Secretary, National Advisory Board on Social Welfare and Health Care Ethics 2014-2017
- Senior Medical Officer, Children and Adolescents Unit, Ministry of Social Affairs and Health 2018
Associate Prof. Jill Hollenbach, PhD
Dr. Hollenbach’s research focuses on analysis of the human leukocyte antigen (HLA) and killer immunoglobulin-like receptor (KIR) immunogenetic systems. Beside their critical role in transplantation, over 100 infectious, autoimmune, cancer and pharmacological diseases are associated with variation of HLA and KIR.
Her work spans the population genetics, evolution, and influence on health of these genes, with emphasis on their role in neurological disease. An additional focus involves understanding how various measures of self-reported race and ancestry relate to genetic ancestry.
Prof. Katherine Hsu, MD, PhD
I am a hematologist and medical oncologist specializing in natural killer (NK) cell biology, stem cell transplantation, and adoptive cell immunotherapy. The major focus of my research is to determine how to use cutting-edge information about NK cells, their genetics and biology, to improve outcomes in the treatment of hematologic malignancies, particularly those treated with stem cell transplantation. Specifically, my laboratory focuses on the molecular interactions between KIR and their HLA ligands that contribute to NK education and inhibition both in vitro and in vivo. Identification of the relative strengths of these interactions and how they affect innate immune clearance of leukemia and viruses will lead to more sophisticated genetic algorithms in donor selection for stem cell transplantation. More broadly applied, a deeper understanding of KIR-HLA control of NK function will inform interventions that can release higher NK activity against viral infection and malignancy.
Prof. Dr. Carolyn Hurley
Dr. Hurley is a tenured professor in the Departments of Oncology, and Microbiology and Immunology at Georgetown University in Washington DC and a member of the Lombardi Comprehensive Cancer Center. Her research program in immunogenetics has focused on how genetic diversity impacts the structure and function of immune response molecules (HLA and KIR). With over 25 years of teaching experience in graduate and medical school courses, Hurley has been honored as a master teacher for the Georgetown medical school. On the clinical side, she is board certified in histocompatibility and oversees a clinical lab primarily typing newly recruited volunteers for the unrelated donor registry in the United States. Hurley has been a member of the National Marrow Donor Program Histocompatibility Advisory Committee since 1992 and a member of the World Marrow Donor Association since 1996. Working within the WMDA, she has helped the organization develop standards and an accreditation process for registries involved in international donor exchange and a web-based training programs for search coordinators.I am a hematologist and medical oncologist specializing in natural killer (NK) cell biology, stem cell transplantation, and adoptive cell immunotherapy. The major focus of my research is to determine how to use cutting-edge information about NK cells, their genetics and biology, to improve outcomes in the treatment of hematologic malignancies, particularly those treated with stem cell transplantation. Specifically, my laboratory focuses on the molecular interactions between KIR and their HLA ligands that contribute to NK education and inhibition both in vitro and in vivo. Identification of the relative strengths of these interactions and how they affect innate immune clearance of leukemia and viruses will lead to more sophisticated genetic algorithms in donor selection for stem cell transplantation. More broadly applied, a deeper understanding of KIR-HLA control of NK function will inform interventions that can release higher NK activity against viral infection and malignancy.
Prof. Dr. Frank Kargl
Frank Kargl is a professor for Distributed Systems at Ulm University. His research interests includes security and privacy in networked control systems and the Internet of Things which he investigates in a broad range of systems like self-driving cars, medical systems, or industrial control systems. Research challenges that we address include privacy-preserving data collection and processing using mechanisms like homomorphic encryption and intrusion and misbehaviour detection in cyber-physical systems.
Prof. Dr. Nicolaus Kröger
Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany. Following the completion of his medical degree, he visited the MD Anderson Hospital, Houston, USA. Prof. Kröger is board certified in Hematology-Oncology and Internal Medicine.
From 2006 to 2012 he served as chairman of the MDS subcommittee of the European Group for Blood and Marrow Transplantation (EBMT), and since 2012 he is the chairman of the Chronic Malignancies Working Party and board member of EBMT, and since 2014 also the chairman of the Scientific Council of EBMT. In 2018 he was elected as President of EBMT (2018-2022)
He is currently also chairman of the German Stem Cell Working Group (DAG-KBT) and member of several editorial boards such as Blood, Haematologica and Bone Marrow Transplantation. He is also member of the Scientific Program Committee and the Editorial Board of the European Hematology Association (EHA) and member of the Scientific Committee of the European School for Hematology (ESH). Additional memberships include societies such as the American Society of Hematology (ASH), European Hematology Association (EHA), European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) , the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and the International Myeloma Working Group (IMWG).
He has received several awards for his work to date including the prestigious EBMT van Bekkum Award in 2015.
Prof Kröger has co-organized several international meetings such as the “1st and 2nd NCI Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation” in Bethesda/USA 2009 and 2012 and a 3rd workshop 2018´6 in Hamburg/Germany, “Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)” in Berlin/Germany 2011, 2013 and 2015 and “Modern Trends in Human Leukemia” in Wilsede/Germany 2014 and 2016.
His research interest is on stem cell biology and stem cell transplantation, the detection and treatment of minimal residual disease by adoptive immunotherapy or novel drugs, the impact of NK-cell allo-reactivity, optimizing outcome with HLA-mismatched donor, and prevention and treatment of chronic graft-versus- host disease.
Prof. Kröger has published extensively in his area of expertise and has contributed to more than 500 publications in peer-reviewed journals such as NEJM, Lancet, JCO, JNCI, PNAS, Blood and Leukemia
Dr. Neema Mayor, PhD
Dr Neema Mayor is Head of Immunogenetics Research at the Anthony Nolan Research Institute and is an Honorary Lecturer in the Cancer Institute at University College London. She is also a Councillor on the European Federation for Immunogenetics (EFI) Executive Committee and a member of the Editorial Board of the journals ‘Human Immunology’ and ‘HLA’.
Neema has worked at Anthony Nolan since 2001 as part of the Patient/Donor project, an on-going study that aims to identify how genetic and clinical factors of the patient and donor impact on haematopoietic cell transplant (HCT) outcome. She obtained her PhD from University College London while at Anthony Nolan in the group of Professor Steven Marsh. Her PhD studies demonstrated the impact of NOD2 polymorphisms on relapse rates and mortality for recipients of an unrelated donor HCT with an acute leukaemia.
Neema’s research is currently focussed in two areas; firstly the development and implementation of novel methods to detect genetic polymorphism and secondly, analysing the impact of HLA and non-HLA genetic variants on HCT outcome in the UK transplant population. Recently Neema was responsible for the development of the third generation sequencing method Single Molecule Real-Time (SMRT) DNA sequencing for clinical HLA typing and aided in the transition of the technology from a research tool to a high-throughput, ISO 15189 accredited technique. Her current research projects are looking at how HLA matching at the level of resolution achievable with SMRT sequencing impacts on the outcome of stem cell transplants, as well as using this technique to identify other genetic markers that may be associated with better survival prognoses.
Neema has been awarded the Invitrogen Young Scientist at the 18th BSHI meeting (2007), the van Bekkum Award at the European Society for Blood and Marrow Transplantation (EBMT) meeting (2007), and the International ASHI Scholar Award at the American Society for Histocompatibility and Immunogenetics (ASHI) meeting (2014) for her research work.
Dena Mercer is the Director of the OneMatch Stem Cell & Marrow Network at Canadian Blood Services, based in Ottawa, Ontario, Canada. Her portfolio also includes oversight of the Quality Management System for Canadian Blood Services’ Donation and Transplantation division.
Dena has been involved with the World Marrow Donor Association for several years as a reviewer with the Accreditation program, and as a member of the Standards committee. She was recently elected as Chair of the WMDA Standards committee.
Dena holds two undergraduate degrees, certification in project management, and a Master of Business Administration.
Dr. Dr. Carlheinz Müller
Carlheinz Mueller holds an MSc in mathematics and physics from the University of Munich and an MD and a PhD in molecular bioinformatics from the University of Ulm. He is certified specialist in Transfusion Medicine as well as in Transplantation lmmunology and Immunogenetics (DGI and UEMS-EBS).
In the 1980s he has been mainly working as a developer for medical software with a focus on tissue typing and immunohematology and also co-founded an IT company. He later joined the University and Red Cross Blood Bank in Ulm as a resident in transfusion medicine. Since its foundation in 1992, he has been Medical Director of ZKRD Zentrales Knochenmarkspender-Register Deutschland (German National Bone Marrow Donor Registry) and since 1997 he has been also its CEO. His main research interests are in bioinformatics and population genetics applied to the field of HLA and stem cell transplantation.
Carlheinz Müller is active in many national and international committees and organizations. In particular, he is the current President of the World Marrow Donor Association (WMDA), President Elect of the German Society for Immunogenetics (DGI), a member of the WHO Nomenclature Committee for Factors of the HLA System and a councilor for the International Histocompatibility Workshops.
Prof. Dr. Effie Wang Petersdorf, MD
Effie Wang Petersdorf, M.D. is Professor, Division of Oncology and Department of Medicine, University of Washington School of Medicine; Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Attending Physician, Seattle Cancer Care Alliance. She earned her A.B in 1978 from Harvard University, and M.D. in 1982 from McGill University. She completed her residency in internal medicine and fellowship in oncology at the University of Washington before joining the Fred Hutchinson Cancer Research Center in 1987. Dr. Petersdorf has devoted her research to the immunogenetics of the HLA system in transplantation. She combines her year-round laboratory research with attending on the stem cell transplant clinical services at the Seattle Cancer Care Alliance. President Bill Clinton awarded her the Presidential Early Career Award for Scientists and Engineers in 1999. Dr. Petersdorf is the 2016 recipient of the Ceppellini award from the European Federation for Immunogenetics. She is past President of the American Society for Blood and Marrow Transplantation and the World Marrow Donor Association.
Matt Prestegaard, B.A., Director of IT, CIBMTR has spent 20 years focusing on development of IT systems in the areas of searching & matching, case management, international (business to business) communications and research. In his current role since 2015, he is responsible for oversight of the IT function for the Center for International Blood and Marrow Transplant Research (CIBMTR). Mr. Prestegaard has been an involved member of the broader HCT community during his time employed with the National Marrow Donor Program (NMDP). First, as the chair of the European Marrow Donor Information System (EMDIS) Technical Group and more recently, as chair of the World Marrow Donor Association (WMDA) IT Working Group.
Dr. Christoph Schickardt
Dr. phil. Christoph Schickhardt is a philosopher and post-doc researcher in the ethics of biomedical research at the National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ). He is an associated researcher of the EPOC Program (Ethics and Patient-Oriented Care in Oncology) at the Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital. Christoph was coordinator of the interdisciplinary projects DASYMED: “Big Data in Systems Medicine”, funded by the German Ministry of Education and Research, and EURAT (Ethical and Legal Aspects of Whole Genome Sequencing). Christoph studied philosophy at the universities of Pavia, Italy, and Lausanne, Switzerland, and was awarded a PhD degree in Philosophy (Ethics) with a thesis on Child Ethics by the University of Düsseldorf (Germany) in 2011. His research focuses on ethical and social aspects of new omics technologies in biomedical research and health care. Schickhardt teaches Ethics at the university of Heidelberg.
Dr. Dr. Alexander Schmidt
After working as a physician at the University hospital Heidelberg, Dr. Alexander Schmidt joined the Boston Consulting Group where he focused on customers from the health care sector. Since 2002, he has worked for DKMS in various positions, including CEO of DKMS German Bone Marrow Donor Center and of the affiliates DKMS Life Science Lab and DKMS Cord Blood Bank. Since July 2017, he is Chief Medical Officer of DKMS.
Dr. Rudolf Schwabe
- 1999 – present CEO, Swiss Blood Transfusion SRC (SBT CRS)
- 2004 – 31.12.2010 CEO, Swiss Foundation Blood Stemcells (merged with SBT CRS as per 1.1.2011)
- 2002 – 2004 Vice-president Swiss Bone Marrow Registry
- 2002 – 2006 President Swisscord Association
- 2000 – present Member (2008 – 2012: President) of the Global Advisory Panel for Corporate Governance and Risk Management in RC National Societies (GAP) at the International Federation of Red Cross/Red Crescent, Geneva
- 2009 – 2016 Member of the Executive board of World Marrow Donor Association (as treasurer)
- 2010 – 2014 Member of the Governing Board of Swisstransplant
- 2014 – present Member of the Executive Board of the European Blood Alliance (as treasurer)
- 2014 – 2016 Member of the Executive Board of the Foundation Bone Marrow Donors Worldwide (BMDW)
Dr. Julio Sincero
Dr. Julio Sincero works as a Cloud Consultant at Google where he helps large customers to accelerate their journey to the cloud. Dr. Sincero has 10 years of professional experience as an IT consultant working with clients in the Financial Service, Energy, Automotive and IT industries. Dr. Sincero holds a master’s degree in computational engineering and a doctoral degree in engineering from the University of Erlangen-Nürnberg.
Betina Sørensen, MD
Betina Sorensen graduated in 2001 as a medical doctor from the University of Southern Denmark. Received in 2008 a specialist degree in Immunology. Has been working at dept. of Clinical Immunology at Aarhus University Hospital as a senior consultant since 2011, with main responsibility for the section for stem cells. Besides the registry (Danish Stem Cell Donors – West) this also includes a JACIE accredited donor center, collection center and processing facility. She is the chair of the Danish Society for Clinical Immunology and a member of the national joint committee for autologous stem cell treatment and the national committee for Transplantation. In WMDA she is chair-elect of the Registries Working group.
Prof. Jeff Szer, MD
Jeff Szer AM was the foundation Professor/Director of the Department of Clinical Haematology & Bone Marrow Transplant Service at Royal Melbourne Hospital (RMH) In Aug 2016 the Department became a part of the Victorian Comprehensive Cancer Centre (VCCC) he in which leads the non-malignant haematology group. He is Director of the Western and Central Melbourne Integrated Cancer Service and has been in that position for 7 years. He has clinical research interests in all areas of transplantation and haematology in particular improving the outcomes of treatment for leukaemia, lymphoma and myeloma and the non-malignant conditions of Gaucher disease and paroxysmal nocturnal haemoglobinuria. He has chaired the Scientific Expert Advisory Committee of the ABMDR for over 20 years and has chaired the Medical Working Group and the S(P)EAR Committee for WMDA. He has authored 320 papers in peer-reviewed journals and is the Editor-in-Chief of the Internal Medicine Journal and on the Editorial Boards of several other international journals including Blood Reviews, Blood Cell Therapy, BMC Haematology, Blood Cells Molecules and Diseases and Bone Marrow Transplantation. He is immediate past President of the Worldwide Network for Blood and Marrow Transplantation and is President-Elect of the World Marrow Donor Association.
David Turner, PhD
Dr Turner has a PhD in Transplant Immunology from the University of Manchester, UK and is a Fellow of the Royal College of Pathologists. Dr Turner has over 25 years experience working in the field of H&I in various UK laboratories. Since 2008 he has been the Consultant Clinical Scientist for H&I within the Scottish Blood Transfusion Service (SNBTS). In this role he has given advice on compatibility issues regarding the banking and allocation of CTLs within SNBTS to treat PTLD and has been involved in discussions within the Global Alliance for iPS Therapies (GAiT) on the optimum size of a global iPS (induced pluripotent stem cell) bank to provide HLA matched tissues and cells to the largest proportion of different populations. Dr Turner is also involved in education and training within the field of H&I, chairing the European Federation for Immunogenetics (EFI) Education Committee and acting as secretary for the European Board of Transplant Immunology, bodies which provide qualifications for scientists and clinicians working in clinical laboratories supporting transplantation.
Stefaan Van der Spiegel, MD
Stefaan Van der Spiegel is leading the Commission’s team on substances of human origin within DG SANTE, covering organs, blood, tissues, cells and IVF.
His team develops EU legislation to ensure safety and quality, and policy to support Member States in improving access to these therapies.
In addition he is responsible for DG SANTE contributions to some other Commission initiatives in health innovation, like the Innovative Medicines Initiative (IMI) and the use of Real World Data.
Prior to this, Stefaan was working on market access and pricing for medicinal products within DG Enterprise (current GROW).
Before joining the Commission Stefaan worked as a Strategy consultant for different healthcare actors and industries at McKinsey&Co.
He is trained as a Medical Doctor (MD) and in Business Administration (MBA).